Forest Infasurf Marketing Awaits Resolution Of Abbott Patent Case
Executive Summary
Patent litigation with Abbott is complicating Forest's marketing plans for its lung surfactant Infasurf, which was approved July 1 for "the prevention and treatment of respiratory distress syndrome in neonates."
You may also be interested in...
Forest Infasurf
Marketing of the lung surfactant calfactant will begin in October, following Buffalo federal court ruling that Infasurf does not infringe Abbott's Survanta (beractant) patent. The ruling overturns a lower court decision against Forest in September. Infasurf was approved in July 1998 for respiratory distress syndrome (1"The Pink Sheet" July 13, p. 4)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011